SERA PROGNOSTICS, INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
SERA PROGNOSTICS, INC. (SERA) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $99.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-12
- SERA PROGNOSTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $28.00K, a 69.57% decline year-over-year.
- SERA PROGNOSTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- SERA PROGNOSTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $92.00K, a 61.40% increase year-over-year.
- SERA PROGNOSTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- SERA PROGNOSTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $103.00K, a 29.93% decline from fiscal 2024.
- SERA PROGNOSTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $147.00K, a 19.51% increase from fiscal 2023.
- SERA PROGNOSTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $123.00K.
- SERA PROGNOSTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $0.00.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $99.00K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $28.00K derived: sum of 2 quarters · filed 2026-03-18 | $103.00K 10-K · filed 2026-03-18 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $75.00K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $75.00K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $92.00K derived: sum of 2 quarters · filed 2026-03-18 | $147.00K 10-K · filed 2026-03-18 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $55.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $55.00K 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $57.00K derived: sum of 2 quarters · filed 2025-03-19 | $123.00K 10-K · filed 2025-03-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $66.00K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $66.00K 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $0.00 derived: sum of 2 quarters · filed 2024-03-20 | $0.00 10-K · filed 2024-03-20 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |